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Abstract
Background: The characteristics and natural history of GOLD B COPD patients are not well described. The clinical
characteristics and natural history of GOLD B patients over 1 year in a multicentre cohort of COPD patients in the
COPDMAP study were assessed. We aimed to identify the subgroup of patients who progressed to GOLD D
(unstable GOLD B patients) and identify characteristics associated with progression.
Methods: Three hundred seventy COPD patients were assessed at baseline and 12 months thereafter.
Demographics, lung function, health status, 6 min walk tests and levels of systemic inflammation were assessed.
Students t tests and Mann Whitney-U tests were used.
Results: One hundred seven (28.9%) of patients were categorised as GOLD B at baseline. These GOLD B patients
had similar FEV1 to GOLD A patients (66% predicted). More GOLD B patients were current smokers (p = 0.031), had
chronic bronchitis (p = 0.0003) and cardiovascular comorbidities (p = 0.019) compared to GOLD A. At 12 months, 25.
3% of GOLD B patients progressed to GOLD D. These patients who progressed (unstable patients) had worse health
status and symptoms (SGRQ-C Total, 50.0 v 41.1, p = 0.019 and CAT, 21.0 v 14.0, p = 0.006) and lower FEV1 (60% v
69% p = 0.014) at baseline compared to stable patients who remained in GOLD B.
Conclusions: Unstable GOLD B patients who progressed to GOLD D had a higher level of symptoms at baseline. A
high symptom burden may predict an increased likelihood of disease progression in GOLD B patients.
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Background
Chronic obstructive pulmonary disease (COPD) is a het-
erogeneous condition, comprising different clinical and
pathophysiological features that vary in both presence and
severity between patients [1]. The Global Initiative for
Chronic Obstructive Pulmonary Disease (GOLD) recom-
mends a combined assessment to stratify patients into one
of four categories (A/B/C/D) based on the severity of air-
flow limitation, degree of symptoms and exacerbation risk
[1]. Patients with more symptoms are allocated into
groups B or D and patients with high exacerbation risk
and/or Forced Expiratory Volume in 1 s (FEV1) < 50%
predicted are allocated into groups C or D. There are dif-
ferent pharmacological treatment recommendations for
each category.
GOLD B patients are defined by mild to moderate air-
flow obstruction (FEV1 > 50%), a low exacerbation rate (<2
exacerbations per year and no hospitalisations) and a high
burden of symptoms. Group B patients may deteriorate
and change GOLD category; in the ECLIPSE cohort study,
only 36% of group B patients remained stable after 1 year,
7% and 35% deteriorated to the higher risk categories C
and D respectively, and 22% improved to group A [2]. The
progression of group B patients may be due to FEV1
decline or an increase in exacerbations, or both.
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COPD is often referred to as a progressive disease [1, 3].
However, the ECLIPSE study demonstrated that FEV1 did
not change in some COPD patients over a 3 year follow
up period [2]. The risk factors for greater FEV1 decline in-
cluded current smoking, emphysema and exacerbations
[4]. Recently, Lange, et al. [5], reported that the rate of
FEV1 decline in COPD patients who have a low FEV1 in
early adult life, indicating sub-optimal lung growth, is
lower compared to COPD patients with normal FEV1 in
early adult life (27 mls versus 52 mls/year respectively).
These findings underscore the variation in lung function
decline in COPD, influenced by multiple factors.
There appears to be heterogeneity within group B, as a
subgroup of patients move over time into higher risk
categories. We report a detailed characterisation of the
natural history of GOLD B patients over 1 year in the
COPDMAP cohort study. We describe the clinical fea-
tures of group B compared to group A patients at the
start of the study. We studied the stability of group B
patients over 1 year, and describe the clinical character-




COPD patients aged 40 or over were recruited at 3 sites
(Manchester, Leicester and Imperial/UCL) into the COPD-
MAP prospective observational cohort study (http://
www.copdmap.org). All patients had a physician diagnosis
of COPD, post-bronchodilator (post BD) FEV1/forced vital
capacity (FVC) ratio <0.7 and ≥10 pack year smoking his-
tory. All patients provided written informed consent using
protocols approved by the local Ethics Committees at each
site (11/L0/1630; 10/H/1003/108; 07/H0406/157).
Stable visits were performed at baseline and at 6 month
intervals up to 2 years. At the baseline visit, the demo-
graphic details and exacerbation history were collected.
Symptoms and functional capacity were assessed and pul-
monary function tests performed. Cardiovascular comor-
bidities were categorised as the following; body mass
index (BMI) ≥25, stroke, peripheral vascular disease, high
cholesterol, high blood pressure, heart attack, diabetes,
atrial fibrillation, angina and other relevant cardiac events.
Sputum and blood samples were obtained from patients
at least 6 weeks after an exacerbation episode. These pro-
cedures were repeated at 6 monthly follow up visits; the
yearly visit data is presented here. Exacerbation history
throughout the observation period was based on patient
recall to match how patients were classification at base-
line. Patient recall agrees well with events detected with
daily diary cards [6].
Patients were categorised as GOLD A, B, C or D using
the 2016 GOLD guidelines [1]. Post bronchodilator FEV1
and preceding 1 year exacerbation history were used to
categorise risk, whilst, either the highest COPD assess-
ment test (CAT) or modified MRC Scale (mMRC) score
was used to categorise symptoms. A change in FEV1 > 60
mls over 1 year was used to identify rapid decliners [7].
The following patient reported outcome measurements
were performed; the CAT [8] and St George’s Respiratory
Questionnaire (SGRQ-C) [9] for health status, the mMRC
Scale for dyspnoea [10], and Centre for Epidemiological
Studies Depression Scale (CES-D) for depression [11].
Lung function was assessed by spirometry, plethysmog-
raphy and gas transfer and was performed in accordance
with European Respiratory Society (ERS)/American Thor-
acic Society (ATS) recommendations [12–14]. Reversibil-
ity was performed using salbutamol 400mcg. Fat free mass
(FFM) and fat free mass index (FFMI) were determined by
bioelectrical impedance analysis. Functional capacity was
assessed by the 6 min walk test (6MWT) and performed
in accordance with ATS/ERS standard. [15] A practice
walk was performed if patients had not performed a 6 min
walk test over the preceding 1 year.
Spontaneous and/or induced sputum was processed for
quantitative polymerase chain reaction (qPCR). Selected
sputum plugs were homogenised with phosphate-buffered
saline (PBS) with glass beads and qPCR was performed for
the detection of the common respiratory potentially
pathogenic microorganisms (PPM) H. influenzae, M.cat-
arrhalis and S. pneumoniae as previously described [16].
The threshold for detection for pathogens by qPCR was
1 × 104 copies per ml. Venepuncture was performed and
the samples collected were sent to the local hospital
laboratories for full blood counts (FBC) and C-reactive
protein (CRP) analysis.
Statistical analysis
The Kolmogorov–Smirnov test was applied to determine
the normality of data. Differences in between groups were
performed using unpaired t tests or Mann–Whitney test
for parametric and non-parametric data respectively. Cat-
egorical variables were analysed using chi square test. P <
0.05 was considered statistically significant. Statistical ana-
lyses were performed using GraphPad Prism version 5.00
(San Diego, California; USA).
Results
Three hundred seventy patients completed the baseline
visit; demographics are shown in Table 1. The GOLD cat-
egorisation using the higher of the two symptom scores
was as follows; 9.2% in group A (n = 34), 28.9% in group B
(n = 107), 3.2% in group C (n = 12) and 58.7% in group D
(n = 217) (Fig. 1). Categorisation using only the CAT score
showed that patients in groups A and C would remain in
these groups, whilst 3.7% (4/107) of the group B and 2.3%
(5/217) of the group D patients would be categorised into
groups A and C respectively. Likewise if patients were
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categorised using only the mMRC score, all patients in
group A and C remained in their groups, whilst 31.8%
(34/107) of the group B and 24.9% (54/217) of the group
D patients would be reclassified into groups A and C
respectively.
Table 2 shows the baseline clinical characteristics of
GOLD A and B patients. FEV1 % predicted was similar
between the groups, despite the greater symptoms in
GOLD B patients. There were more current smokers in
group B (36.5% v 15.2% respectively, p = 0.031) and a
significantly higher proportion of group B patients had
chronic bronchitis (57.4% v 21.2%, p = 0.0003) and car-
diovascular comorbidities (82.2% v 61.8% p = 0.019). The
clinical characteristics of GOLD C and D patients are
presented in the data supplement in Additional file 1:
Table S1. The comparison of clinical characteristics be-
tween GOLD B and D patients are shown online in
Additional file 2: Table S2; the number of exacerbations,
symptoms burden and lung function were significantly
worse in GOLD D patients compared to GOLD B.
Seventy five out of 107 GOLD B patients attended for
1 year follow up; the major reasons for this decrease in
numbers were loss to follow up and withdrawal of con-
sent. The majority of patients were stable and remained
in group B at 1 year (68.0%). There were 19 unstable
GOLD B patients (25.3%) who progressed to GOLD D; 8
patients due to a decline in FEV1, 10 patients due to an
increase in exacerbation risk, and 1 subject displayed
both of these characteristics.
The mean change in FEV1 over 1 year was a decline of
66mls (Fig. 2). There was no decline in FEV1 in 23 pa-
tients, whilst 44 patients (58.7%) displayed a decline
greater than 60mls over the year.
At 2 year follow up, 40 out of 107 GOLD B patients
remained in the study. Of those patients who remained
stable at 1 year (n = 28), the majority remained in
group B (n = 15; 53.6%), with a third progressing to
group to D (n = 9; 32.1%). Of the 19 patients who dete-
riorated to GOLD D at 1 year, 12 remained in the study
at 2 years. The majority of patients (n = 8) remained in
group D, while the remaining patients (n = 4) reverted
to group B (Fig. 1).
Table 1 Baseline demographics of patients
Demographic n = 370
Gender (% Male) 65
Age (years) 70.2 (8.8)
Smoking status (Current %) 30.0
Pack years 46.0 [10.0–220.0]
BMI (kg/m2) 26.2 [15.6–49.2]
Exacerbations (1 year prior) 1.0 [0.0–15.0]
Inhaled steroid use % 78.8
Oral steroid use % 3.8
LABA use % 70.7
LAMA use % 75.0
Azithromycin use % 3.5
Post BD FEV1 (L) 1.4 (0.6)
Post BD FEV1 % 57.0 [20.0–117.0]
Post BD Ratio 0.5 [0.2–0.8]
GOLD A n (%) 34 (9.2)
GOLD B n (%) 107 (28.9)
GOLD C n (%) 12 (3.2)
GOLD D n (%) 217 (58.7)
Summaries are presented as percentages, Mean (SD) or Median [Range]
as appropriate
Definitions of abbreviations; BMI body mass index, LABA long acting beta
agonist, LAMA long acting muscarinic antagonist, Post BD post bronchodilator,
FEV1 forced expired volume in first second
Fig. 1 GOLD B progression across 2 years. 107 GOLD B patients at baseline; 75 remained at 1 year and 40 at 2 year. Of these 40 patients, 28 were
categorised as stable and 12 unstable
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Table 2 Baseline characteristics of patients categorised as GOLD A and B
GOLD A (n = 34) GOLD B (n = 107) p value
Demographics
Gender (% Male) 58.8 67.3 0.41
Pack years 44.5 [10.0–135.0] 45 [10.0–220.0] 0.53
Smoking status (% Current) 15.2 36.5 0.031
BMI (Kg/m2) 26.1 [20.6–47.0] 27.2 [16.5–49.2] 0.73
FFMI (Kg/m2) 17.3 [12.9–28.7] 17.6 [10.0–27.0] 0.92
Chronic bronchitis (%) 21.2 57.4 0.0003
Exacerbations (1 year prior) 0.0 [0.0–1.0] 0.0 [0.0–1.0] 0.11
Co-morbidities
Cardiovascular comorbidity any (%) 61.8 82.2 0.019
Comorbidities any (%) 35.3 16.8 0.03
Patient reported outcomes
SGRQ total 19.3 [1.0–40.0] 40.9 [5.7–82.4] <0.0001
SGRQ symptoms 29.5 (16.5) 55.3 (17.8) <0.0001
SGRQ impact 12.0 [3.0–24.0] 25.0 [0.0–75.5] <0.0001
SGRQ activity 34.8 (18.5) 58.9 (22.6) <0.0001
CAT 6.0 [2.0–9.0] 16.0 [4.0–39.0] <0.0001
CES-D 5.0 [1.0–6.0] 11.5 [1.0–4.0] <0.0001
Functional capacity
6MWD (metres) 457.0 [169.0–636.0] 405.7 [119.0–702.0] 0.07
Lung function
Vital capacity % 102.3 (22.5) 100.7 (17.9) 0.73
Total lung capacity % 108.9 (16.1) 109.2 (20.1) 0.96
Residual volume % 130.6 [89.1–179.9] 132.0 [63.0–286.0] 0.90
Inspiratory capacity % 87.1 (23.0) 89.5 (21.3) 0.65
FRC % 125.8 (24.0) 128.7 (33.2) 0.71
DLCO % 70.8 [56.0–116.5] 63.0 [28.0–106.0] 0.05
KCO % 86.8 [64.0–126.5] 76.4 [35.0–137.0] 0.13
VA % 84.2 (13.3) 80.8 (10.7) 0.25
Post FEV1 % 71.0 (15.2) 68.3 (11.4) 0.27
Reversibility % 9.8 [4.0–16.0] 6.7 [−3.0–+38.0] 0.13
Reversibility mls 150.0 [−40.0–+290.0] 100.0 [−80.0–+670.0] 0.21
Bacteriology
Bacterial load (genome copies/ml) 7.11 × 106 [0–1.81 × 1010] 7.74 × 104 [0–4.91 × 108] 0.29
Colonised (% >1 × 104 total PPM) 63.7 55.6 0.75
Systemic inflammation
CRP (mg/L) 3.0 [1.0–22.0] 3.0 [1.0–157.0] 0.35
WBC (109/L) 6.8 [3.6–12.0] 7.3 [5.0–12.6] 0.11
Eosinophils (109/L) 0.2 [0.0–0.8] 0.2 [0.0–0.9] 0.83
Summaries are presented as mean (SD), percentage or Median [Range] as appropriate
Definitions of abbreviations: BMI body mass index, FFMI fat free mass index, SGRQ St George’s Respiratory Questionnaire, CAT COPD Assessment Test, CES-D Centre
for Epidemiologic Studies Depression, 6MWD six minute walk distance, FRC functional residual capacity, DLCO diffusing capacity of the lungs for carbon monoxide,
KCO carbon monoxide transfer coefficient, VA alveolar volume, CRP C-reactive protein, WBC white blood count, PPM potentially pathogenic microorganism
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Table 3 shows the clinical characteristics at 1 year of pa-
tients who remained in group B at 1 year and those who
progressed to group D (stable and unstable patients respect-
ively). At 1 year, unstable patients had significantly more ex-
acerbations over the previous year (means 1.5 v 0.2, p =
<0.0001), higher mean CAT scores (20.0 v 15.5, p = 0.018),
worse mean SGRQ total scores (50.0 v 41.1, p = 0.001),
higher mean C-reactive protein levels (5.0 v 3.0, p= 0.017),
and reduced mean 6MWD (347.3 v 440.5, p = 0.023).
Table 4 shows the characteristics of the stable and un-
stable patients at the baseline visit. Unstable patients
had a significantly lower mean FEV1 % predicted (69.7%
v 62.4%; p = 0.016), worse mean SGRQ score (40.1 v
50.0; p = 0.019) and mean CAT score (14.0 v 21.0; p =
0.006), and higher mean CRP levels with a trend towards
significance (3.0 v 4.5; p = 0.06). Patients who declined
due to FEV1 change had lower FEV1 at baseline (means
55.7% v 67.8%; p = 0.0023), and a much greater magni-
tude of FEV1 deterioration over 1 year (284 mls v 44
mls; p = 0.0021), and were more likely to be current
smokers (62.5% v 10.0%; p = 0.04) (see Additional file 3:
Table S3 in the data supplement).
Discussion
The criteria used to define GOLD B patients results in a de-
gree of homogeneity in terms of symptoms, lung function
and exacerbation history when assessed at a single visit.
However, longitudinal follow up reveals a heterogeneous
course of disease. GOLD B patients who progressed to
GOLD D had more severe disease characteristics at the
start of the 1 year follow up. This unstable subgroup had
significantly worse CAT and SGRQ scores and lower FEV1
compared to stable patients at baseline. Progression of
GOLD B to GOLD D appears to be more likely in highly
symptomatic patients.
Approximately equal numbers of unstable patients de-
teriorated due to FEV1 alone or exacerbations alone (8
versus 10 respectively). Although these are small groups
to perform sub-analysis, there were very clear differences
in the rate of FEV1 decline between these groups (means
284 versus 44 mls respectively), and there were more
current smokers in the former group. The role of
current smoking in promoting lung function decline is
known [4], and we show here a subgroup of group B pa-
tients where current smoking is associated with a very
rapid rate of FEV1 decline. The progression to group D
in these patients was associated with both a lower FEV1
at baseline and a large decrease in FEV1 over 1 year
(mean 284 mls). This indicates that switching from
group B to D because of FEV1 criteria is not simply due
to small changes in lung function that might occur in
patients with lung function measurements just above the
FEV1 50% predicted threshold.
The worse patient reported outcome scores at baseline
in unstable group B patients suggest increased disease ac-
tivity. The deterioration of group B patients towards group
D is likely to have started before the baseline visit in many
of these patients. The high symptom burden is probably
related to increased disease activity associated with rapid
FEV1 decline. Alternatively, for patients who progressed
to group D because of exacerbations, the higher symptom
burden may be due to mild or unreported exacerbations
in the previous year, which subsequently evolved to mod-
erate to severe exacerbations during the follow up period.
Different thresholds have been used to define COPD pa-
tients with a rapid decline in FEV1; 40 mls/year has been
suggested [17], while 60 mls/year has also been used [7].
We observed a mean decrease of 66 mls/year, with 58.7%
of patients showing >60 ml decline. This is a higher mean
rate of FEV1 decline than previously observed in many co-
hort studies and clinical trials [18, 19]. However, Koskela
et al. [20] recently reported one third of patients with
rapid declining FEV1 had a mean decrease of 78 mls/year
compared to the 28 mls/year in the rest of the patients.
Here we focused just on group B patients. FEV1 decline is
known to vary with GOLD stage 1–4 and with GOLD
group A-D. Goosens et al. [18] reported a mean 48 mls/
year decline in FEV1 in GOLD B patients, while Kim et al.
[19] reported a smaller mean decline of 27 mls/year in
GOLD B patients. Our higher rate of decline compared to
these previous reports in group B patients may reflect the
recruitment strategy used, focusing on hospital clinics and
therefore recruiting more severe/symptomatic patients.
This lung function decline could not be explained by
changes in medication as patients remained on their nor-
mal medications when entering this observational study.
In the ECLIPSE study, 36% of group B patients remained
stable, while 35% progressed to group D after 1 year and
22% improved to group A [2]. In our COPDMAP cohort, a
Fig. 2 Change in post bronchodilator FEV1 in GOLD B over 1 year.
58.7% of GOLD B patients displayed rapid decline in FEV1
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slightly lower proportion (25%) progressed to group D, but
many more remained stable (68%). ECLIPSE was a world-
wide study while COPDMAP is a UK study, and these dif-
ferences may simply reflect the varied healthcare of the
patients in different studies and locations.
Significantly more group B patients were current smokers
compared to group A. Furthermore, group B had more
comorbidities and a greater prevalence of chronic bron-
chitis compared to group A patients. Despite these differ-
ences, and a higher symptom burden in group B, there
were no differences in lung function between groups. Simi-
larly, previous studies have reported similar lung function
in group B compared to group A patients [19]. These
findings highlight that the increased symptom burden,
Table 3 Comparison of 1 year characteristics of patients who remained stable (GOLD B) and unstable patients (GOLD D) from
baseline
GOLD B (n = 51) GOLD D (n = 19) p - value
Demographics
Gender (% Male) 75.6 52.6 0.15
BMI (Kg/m2) 27.0 [16.2–44.8] 27.7 [21.7–48.5] 0.32
FFMI (Kg/m2) 18.3 [8.8–24.0] 17.6 [11.7–27.0] 0.75
Exacerbations (1 year prior) 0.0 [0.0–1.0] 2.0 [0.0–4.0] <0.0001
Patient reported outcomes
SGRQ total 41.1 (15.5) 50.0 [22.2–82.3] 0.001
SGRQ symptoms 54.6 (19.9) 61.0 (17.5) 0.24
SGRQ impact 26.3 [2.1–71.6] 42.4 [4.6–60.1] 0.05
SGRQ activity 59.3 [0.0–100.0] 78.1 [22.5–100.0] 0.003
CAT 15.5 [9.0–35.0] 20.0 [9.0–37.0] 0.018
CES-D 12.0 [0.0–33.0] 15.0 [0.0–31.0] 0.58
Functional capacity
6MWD (metres) 440.5 (125.7) 347.3 (123.4) 0.023
Lung function
Vital capacity % 99.2 (21.9) 93.6 (13.1) 0.40
Total lung capacity % 110.2 (17.0) 110.5 (23.5) 0.96
Residual volume % 132.0 (30.4) 150.0 (55.9) 0.16
Inspiratory capacity % 93.1 (21.8) 91.4 (20.9) 0.81
FRC % 125.6 (25.7) 132.5 (45.9) 0.52
DLCO % 56.5 [40.0–102.0] 61.5 [32.0–115.0] 0.87
KCO % 75.5 (80.1) 74.7 (85.0) 0.53
VA % 81.4 (13.1) 76.9 (14.2) 0.29
Post FEV1 % 68.2 (12.3) 57.3 (12.8) 0.002
Reversibility % −4.4 [−53.8–+8.0] −8.1 [17.3–+8.3] 0.25
Reversibility mls 20.0 [−170.0–580] 90 [−120–200] 0.90
Change in FEV1 from baseline −80.0 [−420.0–+939.0] −120.0 [−531.0–+180.0] 0.07
Bacteriology
Bacterial load (genome copies/ml) 2.36 × 106 [0–8.89 × 108] 10.3 × 107 [0–1.76 × 108] 0.25
Colonised (% >1 × 104 total PPM) 71.4 77.2 1.00
Systemic inflammation
CRP (mg/L) 3.0 [1.0–20.0] 5.0 [2.0–20.0] 0.017
WBC (109/L) 6.9 [3.6–13.5] 7.5 [4.8–11.8] 0.73
Eosinophils (109/L) 0.2 [0.1–0.6] 0.2 [0.0–0.4] 0.24
Summaries are presented as mean (SD), percentage or Median [Range] as appropriate
Definitions of abbreviations: BMI body mass index, FFMI fat free mass index, SGRQ St George’s Respiratory Questionnaire, CAT COPD assessment test, CES-D Centre
for Epidemiologic Studies Depression, 6MWD six minute walk distance, FRC functional residual capacity, DLCO diffusing capacity of the lungs for carbon monoxide,
KCO carbon monoxide transfer coefficient, VA alveolar volume, CRP C-reactive protein, WBC white blood count, PPM potentially pathogenic microorganisms
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Table 4 Baseline characteristics of patients who remained stable (GOLD B) and unstable patients (GOLD D) at 1 year
Stable (n = 51) Unstable (n = 19) p - value
Demographics
Gender (% Male) 72.5 52.6 0.15
Pack years 45.0 [10.0–220.0] 52.0 [10.0–113.0] 0.67
Smoking status (% Current) 37.3 36.8 1.00
BMI (Kg/m2) 27.2 [17.3–49.2] 27.9 [20.7–45.0] 0.28
FFMI (Kg/m2) 17.8 (3.4) 18.7 (3.4) 0.34
Chronic bronchitis (%) 58.3 61.1 1.00
Exacerbations (1 year prior) 0.0 [0.0–1.0] 0.0 [0.0–1.0] 0.88
Co-morbidities
Cardiovascular comorbidity any (%) 94.1 94.7 1.00
Comorbidities any (%) 94.1 94.7 1.00
Patient reported outcomes
SGRQ total 40.1 [14.6–80.0] 50.0 [22.2–82.3] 0.019
SGRQ symptoms 55.1 [22.0–91.0] 60.8 [15.4–90.0] 0.10
SGRQ impact 26.0 [2.5–71.6] 35.9 [9.0–73.7] 0.20
SGRQ activity 59.3 [7.6–100.0] 79.0 [15.6–100.0] 0.003
CAT 14.0 [4.0–28.0] 21.0 [8.0–39.0] 0.006
CES-D 11.0 [1.0–32.0] 12.5 [3.0–38.0] 0.94
Functional capacity
6MWD (metres) 425.3 (98.5) 361.5 (124.8) 0.06
Lung function
Vital capacity % 103.3 (19.8) 96.6 (16.5) 0.25
Total lung capacity % 108.8 (19.9) 111.8 (24.6) 0.65
Residual volume % 130.9 (37.4) 150.4 (60.2) 0.16
Inspiratory capacity % 87.0 (23.0) 89.8 (16.1) 0.67
FRC % 129.3 (30.7) 134.2 (44.5) 0.65
DLCO % 66.2 (20.3) 64.1 (24.3) 0.76
KCO % 75.5 [41.2–137.0] 81.5 [35.0–124.0] 0.97
VA % 82.8 (12.0) 79.2 (9.3) 0.32
Post FEV1 % 69.7 (11.7) 62.4 (9.0) 0.016
Reversibility % 5.0 [−3.0–+33.0] 7.4 [0.8–32.0] 0.47
Reversibility mls 90.0 [−40.0–+670.0] 95.0 [20.0–+380.0] 0.90
Bacteriology
Bacterial load (genome copies/ml) 1.44 × 105 [0.0–2.43 × 108] 7.4 × 102 [0–10.4 × 107] 0.66
Colonised (% >1 × 104 total PPM) 66.7 46.2 0.30
Systemic inflammation
CRP (mg/L) 3.0 [1.0–35.5] 4.5 [1.0–157.0] 0.06
WBC (109/L) 7.2 [5.4–12.6] 7.4 [5.0–12.6] 0.42
Eosinophils (109/L) 0.2 [0.0–0.9] 0.2 [0.1–0.3] 0.32
Summaries are presented as mean (SD), percentage or Median [Range] as appropriate
Definitions of abbreviations: BMI body mass index, FFMI fat free mass index, SGRQ St George’s Respiratory Questionnaire, CAT COPD Assessment Test, CES-D Centre
for Epidemiologic Studies Depression, 6MWD six minute walk distance, FRC functional residual capacity, DLCO diffusing capacity of the lungs for carbon monoxide,
KCO carbon monoxide transfer coefficient, VA alveolar volume, CRP C-reactive protein, WBC white blood count, PPM potentially pathogenic microorganisms
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including increased breathlessness, in group B patients is
not attributed to airflow obstruction alone, and further un-
derscores the poor relationship between lung function and
symptoms in COPD patients. The increased symptom bur-
den in GOLD B patients is likely to be due, at least in part,
to the increased prevalence of co-morbidities.
Other cohort studies have not reported lower rates of
current smoking in group A patients compared to group
B [19, 21, 22]. Our relatively small number of group A pa-
tients means that the estimate of current smokers in our
study is not robust.
We only had a small number of patients who attended
for 2 year follow up, but nevertheless the pattern of ap-
proximately 25% further switching to group D in the sec-
ond year was observed. Furthermore, the majority of
patients who had progressed to group D after 1 year
remained in this category at 2 years.
A key strength of the current study is the detailed
characterisation of the GOLD B group. Potential limita-
tions are the sample sizes for subgroup analysis, and the
dropout rate during longitudinal follow up.
Conclusion
In conclusion, we show that a subset of GOLD B pa-
tients who moved to the higher risk D category after
1 year had greater symptoms and worse health status at
the start of the study. Patient reported outcome scores
appear to be related to the risk of disease progression in
this GOLD category. Within GOLD B there also appears
to be a subgroup with a very high rate of lung function
decline associated with current smoking. These findings
demonstrate the heterogeneous nature of GOLD B pa-
tients during longitudinal follow up, and that this group
of patients who are at risk of disease progression should
be carefully followed-up in clinical practice.
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